Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MasterAlgaeon Jun 05, 2021 9:55am
304 Views
Post# 33335783

Crystal Ball and Company Updates

Crystal Ball and Company Updates
I think that updates and progress on their pipeline are expected, the efficacy of H2S has already been demonstrated.
So people will be disappointed if they expect the market capitalization to change at all with a positive update. However - if the updates even express a whiff of extended timelines that will be very negative for the market capitalization.
 
According to my crystal ball - What's important and going to change the market capitalization is a partnership announcement. I'm not expecting any buyout of 346, and crystal ball says not-going-to-happen...
 
A partnership would demonstrate to institutions a vote of confidence in the platform.
 
The crystal ball says - Moving to the NASDAQ would help mitigate currency risk for American institutional investment and indicate confidence in a partnership deal close at hand.
Although a move and partnership would likely happen at the same time.

The crystal ball says a move to NASDAQ is linked closely with a partnership deal.
When crystal ball, when!
Crystal ball says: three, four or five moons...
<< Previous
Bullboard Posts
Next >>